

- Abd-El-Barr, T.M. and Refaat, L.A. (2002) :** The influence of aprotinin, haemofiltration, or both on proinflammatory cytokines in pediatric patients undergoing surgical correction of congenital acyanotic heart diseases. *Eg. J. Anaesth.*, 18: 15-13.
- Andrews, R.K.; Lopez, J.A.; Berndt, M.C. (1997) :** Molecular mechanisms of platelet adhesion and activation. *Int. J. Biochem. Cell Biol.*, 29:91.
- Bagge, L.; Lilienberg, G.; Nystrom, S. and Tyden, H. (1986) :** Coagulation fibrinolysis and bleeding after open-heart surgery. *Scand. J. Thorac. Cardiovasc. Surg.*, 20:151.
- Bergqvist, D.; Benoni, G.; Bjorgell, O. et al. (1996) :** Low molecular weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. *N. Engl. J. Med.*, 335:696-700.
- Bick, R.L.; Frazier, B.L. and Saunders, C.R. (1984) :** Alterations of hemostasis during cardiopulmonary bypass: The potential role of factor X II in inducing primary fibrinolysis. *Blood*, 64:A926.

- Blauhut, B.; Gross, C.; Necek, S.; Doran, J.; Spath, P. and Hasen, P. (1991) :** Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after CPB. *J. Th. Card. Vas. Surg.*, 101:958-67.
- Body, S.C. (1996) :** Platelet activation and interactions with the microvascular. *J. Cardiovasc. Pharmacol.*, 27:513.
- Bombeli, T.; Muller, M.; Haeberli, A. (1997) :** Anticoagulant properties of the vascular endothelium. *Thromb. Haemost.*, 77:408.
- Boyle, E.; Verrier, E. and Spiess, B. (1997) :** The procoagulant response to injury. *Ann. Thoracic. Surg.*, 64:516-23.
- Brister, S.J.; Ofosu, F.A.; Heigenhauser, G.J.E. et al. (1994) :** Is heparin the ideal anticoagulant for cardiopulmonary bypass? Dermatan sulphate may be an alternate choice. *Thromb. Haemost.*, 71:468-473.
- Bruce, D.S. (1995) :** Monitoring metabolic indices and coagulation / haemostasis. In : *Monitoring in Anaesthesia and Critical Care Medicine*. 3rd ed. Churchill Livingstone, New York, pp. 588-599.

- Bull, B.S.; Korpman, R.A.; Muse, W.M. (1975) :** Heparin therapy during extracorporeal circulation. *J. Thorac. Cardiovasc. Surg.*, 69:674-689.
- Butler, J. Rocker, G.M. and Westaby, S. (1993) :** Inflammatory response to cardiopulmonary bypass. *Ann. Thorac. Surg.*, 55:55-9.
- Butterworth, J.F.; James, R.L.; Kennedy, D.J. et al. (1996) :** Pharmacokinetics of e-aminocaproic acid in adult patients undergoign coronary artery surgery. *Anaesthesiology*, 85:A151.
- Chong, B.H. (1995) :** Heparin induced thrombocytopenia. *Br. J. Haematol.* 89:431-439.
- Christiana, M.M.; Laureen, H.; Christopher, R.C. et al. (1999) :** Cardiopulmonary bypass and the anaesthesiologist. In : *Cardiac Anaesthesia "Joel A. Kaplan"*. 4th ed. W.B. Saunders Company, London, pp. 10961-1097.
- Claus Bartels; Ania Gerdes; Jorg Babin-Ebel et al. (2002) :** Cardiopulmonary bypass : Evidence on experience based? *J. Thorac. Cardiovasc. Surg.*, 124:20-7.
- Clemetson, K.J. (1999) :** Primary haemostasis : sticky fingers cement the relationship. *Current concepts of the*

basic mechanisms of platelet aggregation and hemostatic plug formation. *Curr. Biol.* 9:R110.

Colman, R.W.; White, J.V.; Scovell, S. et al. (1999) : Kininogens are antithrombotic proteins in vivo. *Arterioscler. Thromb. Vasc. Biol.*, 19:2245-2250.

Condo, N.I.; Maddi, R. Ewenstein, B. and Guldhaber, S.Z. (1994) : Anticoagulation and hemostasis in cardiac surgical patients. *J. Cardiovasc. Surg.*, 9:443-61.

D'Ambra, M. (1996) : Restoration of normal coagulation process : Advances in therapies to antagonize heparin. *J. Cardiovasc. Phar.*, 27:S58.

David, C.L. (1997) : Haematological disorders in R.L. Souhami Text Book of Medicine. 3rd ed. Churchill Livingstone New York, pp. 1029-1044.

Davie, E.W.; Fujikawa, K.; Kiesel, W. (1991) : The coagulation cascade: Initiation, maintenance, and regulation. *biochemistry*, 30:10363-70.

Davies, G.C.; Sobel, M.; Salzman, E.W. (1980) : Elevated plasma fibrinopeptide A and thromboxane B₂ levels during cardiopulmonary bypass. *Circulation*, 61:808.

De Smet, A.; Joen, M.C.; Van Overen, W.R.; Roozendaal, K.;

Harder, M.; Eijnsman, L. and Wildevuur, C. (1990) :
Increased anticoagulation during CPB by Aprotinin.
J. Thora. Cardiovasc. Surg., 100:520-7.

Despotis, G.L.; Filos, K.S.; Zoys, T.N. et al. (1996) : Factors
associated with excessive postoperative blood loss
and hemostatic transfusion requirements : A
multivariate analysis in cardiac surgical patients.
Anesth. Analg., 82:13-21.

Ditto, F.F. and Gibbons, J.J. (1991) : Factitious prolongation of
bleeding time associated with patient movement.
Anaesth. Analg., 72:710-2.

Eligah, W. Muriithi; Philip Belcher, Jangan, N. Race et al. (2000):
The effect of heparin and extracorporeal circulation
on platelet counts and platelet microaggregation
during CPB. J. Thorac. Cardiovasc. Surg., 120:538-
43.

Erturgrulozal, Erkan Koralay, Hakon Bingol et al. (2002) : Does
tranexamic acid reduces desmopressin-induced
hyperfibrinolysis? J. Thorac. Cardiovasc. Surg.,
123:539-43.

**Gilliland, H.E.; Armstrong, M.A.; Uprichard, S.; Clarke, G. and
McMurray (1999) :** The effect of aprotinin on



interleukin-8 concentration and leukocyte adhesion molecule expression in an isolated CPB system. *Anesthesia*, 54:427-433.

Gravlee, g.P.; Haddon, W.S.; Rothberger, H.K. et al. (1999) : Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation. *J. Thorac. Cardiovasc. Surg.*, 99:518-527.

Greilich, P.E.; Carr, M.E.; Chang, A.S. (1995) : Reduction in platelet force development by cardiopulmonary bypass are associated with haemorrhage. *Anaesth. Analg.*, 80:449-465.

Guyton, A.C.; Hall, J.E. (1996) : Text book of medical physiology. 9th ed. W.B. Saunders Co., Philadelphia Londin, pp. 218-266.

Hakim, T.S.; Picone, A.; Oleary, C.E. et al. (1995) : Protamine induced pulmonary vasoconstriction in heparinized pigs. *Anaesth. Analg.*, 81:38-43.

Harker, L. (1999) : Bleeding after cardiopulmonary bypass. *N. Engl. J. Med.*, 314:1446.

- Harmon, D.E. (1996) :** Cost benefit analysis of pharmacologic haemostasis. *Ann. Thorac. Surg.*, 61 (2 suppl.) S21-S25.
- Harvery, D.W.; Bernard, J.G.; Lional, H.O. (2001) :** Anti-thrombotic agents in drugs for the meart. 5th. W.B. Saundrs Company, London, pp. 273-313.
- Hass, S.; Walenga, J.M.; Jeske, W.P.; Fareed, J. (1999) :** Heparin-induced thrombocytopenia: The role of platelet activation and therapeutic implications. *Semin Thromb. Haemost.*, 25 (suppl. 1):67-75.
- Hett, D.A.; Walker, D.; Pilkington, S.N.; Smith, D.C. (1995) :** sonoclot analysis. *Br. J. Anaesth*, 75:771-776.
- Hill, G.E.; Taylor, J. and Robbins, R.A. (1997) :** Differing effects of aprotinin and EACA on cytokine-induced inducible nitrix oxide synthase expression. *Ann. Thorac. Surg.*, 63:747.
- Horrow, J.C.; Halvacek, M.D.; Strong, W.; Collier, Brodsky, J.; Goldman, S.M. and Goel, I.P. (1990) :** Prophylactic tranexamic acid decreases bleeding after cardiac operation. *J. Th. Card. Vas. Surg.*, 99:70-4.
- Horrow, J.C.; Van Riper, D.F.; Strong, M.D. et al. (1991) :** Hemostatic effects of tranexamic acid and

cardial infarction), *Jordan Journal of Anaesthesia*, 3-24.

Mattox, K.L.; Guinn, G.A.; Rubio, P.A. et al. (1998) : Use of the activated coagulation time in intraoperative heeparin reversal for cardiopulmonary operations. *Ann. Thorac. Surg.*, 19:34-638.

Menichetti, A.; Tritapepe, G.; Ruvolo, G.; Speziale, Colgliati, Di-Giovanni, Pacilli, M. and Criniti, A. (1996) : Changes in coagulation patterns, blood loss, and blood use after CPB: aprotinin Vs tranexamic acid Vs-EACA. *J. Card. Vas. Surg.*, 37:401-7.

Michael Poullis, Richard Monning, M.; Kelaffin et al. (2002) : The antithrombotic effect of aprotinin : action mediate. *J. Thorac. Cardiovasc. Surg.*, 120:370-8.

Michael, Swash (1995) : The blood. In : *Hutchison's Clinical Methods*. 20th ed. W.B. Saunders Co. London, pp. 411-425.

Michelson, E.L.; Torosian, M.; Morganorth, J. et al. (1980) : Early recognition of surgically correctable causes of excessive mediastinal bleeding after coronary artery bypass graft surgery. *Am. J. Surg.* 139:313.



- Mojcik, C.F. and Levy, J.H. (2001) :** Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. *Ann. Thorac. Surg.*, 71:754-54.
- Mongan, P.D.; Hosking, M.P. (1992) :** The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. *Anesthesiology*, 77:38-46.
- Morel, D.; Costabella, P. and Pittet, J. (1990) :** Adverse CPB effects and increased thromboxane concentrations following neutralization of heparin with protamine in awake sheep are infusion rate dependent. *Anesthesiology*, 73:415-424.
- Nesheim, M.E.; Wang, W.; Boffa, M. et al. (1997) :** Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. *Thromb. Haemost.*, 78:386.
- Norig, E. and Jan, C.H. (2000) :** Coagulation and coagulopathies. In : *Cardiovascular and Thoracic Anaesthesia*. 1st ed. Churchill Livingstone New York, pp. 779-791.
- Piet Zorgdroff; Gerand Von den Bos and Geert Tongelder (2000):** Extracorporeal circulation can induce hypotension by both blood material contact and pump-induced platelet aggregation. *J. Thorac. Cardiovasc. Surg.*, 120:12-9.

- Pineo, G.F.; Hull, R.J. (1997) :** Low-molecular weight heparin : prophylaxis and treatment of venous thrombo-embolism. *Annu. Rev. Med.*, 48:79.
- Pourard, Philippe (1998) :** Review of efficacy parameters. *Ann. Thora. Surg.*, 65:540-4.
- Reich, D.L.; Zahl, K.; Perucho, M.H.; Thys, D.M. (2000) :** An evaluation of two activated clotting time monitors during cardiac surgery. *J. Clin Monit.*, 8:33-36.
- Riper, V.; Horrow, J.C. and Osborne, D. (1990) :** Is the thromboelastograph a clinically useful predictor of blood loss after bypass? *Anesthesiology*, 73:3A, A1206.
- Robert, K. Steolting and Stephen, F. Dierdrof (1998) :** Coagulation disorders. In : *Anaesthesia and Co-existing Disease*. 3rd ed. Churchill Livingstone Inc, New York, pp. 407-425.
- Royston, D. (1992) :** High dose Aprotinin therapy: A review of the first five years' experience. Review Article. *J. of Cardiothorac. and Vascular Anesthesia*, 6:76-100.

- Royston, D. (1995) : Blood sparing drugs : Aprotinin, tranexamic acid and e-aminocaproic acid. *Int. Anaesthesiol. Clin.*, 33:155.
- Russell, D.H.; Raskob, G.E. and Brant, R.F. et al. (2000) : Low molecular weight heparin versus heparin in treatment of patients with pulmonary embolism. *Ar. Int. Med.*, 160 (2) 229-336.
- Schmahl, K.S.; ganjoo, A.K.; Harloff, M.G. (1997) : Orgaran (Org 10172) for cardiopulmonary bypass in heparin-induced thrombocytopenia: Role of adjunctive plasmapheresis. *J. Cardiothorac. Vasc. Anesth.*, 11:262-264.
- Shattil, S.J.; and Bennet, J.S. (1981) : Platelet and their membrane in haemostasis: physiology and pathophysiology. *Ann. Intermed.*, 94:108.
- Shirhy, J.F. and Andrew, J.M. (2000) : Haematological consideration. In : *Anaesthesia for Vascular Surgery*. 1st ed. Arnold Publisher, pp. 232-248.
- Shorten, G.D.; Comunale, M.E. (1996) : Heparin-induced thrombocytopenia. *J. Cardiothorac. Vasc. Anesth.*, 10:521-530.

- Slaughter, T.F. and Greenberg, C.S. (1997) :** Heparin associated thrombocytopenia and thrombosis: implications for perioperative management. *Anaesthesiology*, 87:667-675.
- Speidel, C.M. (1996) :** Procoagulant activity on injured arteries and associated thrombosis mediated primarily by the complex of tissue factor and factor VIIa. *Coron Artery Dis.*, 7:57.
- Spiess, B.D. (1995) :** Thromboelastography and cardiopulmonary bypass. *Semin Thromb. Hemost.*, 21 Suppl., 4:27-33.
- Stamama, C.; Quezada, R.; Riou, B. et al. (1994) :** Intraoperative measurement of activated partial thromboplastin time and prothrombin time with a new compact moniotr. *Acta Anaesthesiol. Scand.*, 38:232-237.
- Stead, S.W. (1999) :** Comparison of two methods for heparin monitoring: A semi-automated heparin monitoring device and activated clotting time during extracorporeal circulation. *Int. J. Clin. Monit. Comput.*, 6:247-254.
- Stenbjerg, S.; Berg, E.; Alrechtsen, O.K. (2000) :** Heparin levels and activated clotting time (ACT) during open heart surgery. *Scand. J. Haematol.*, 26:281.



- Szalados, J.E.; Ouriel, K.; Shapiro, J.R. (1994) : Use of the activated coagulation time and heparin dose-response curve for the determination of protamien dosage in vascular surgery. *J. Cardiothorac. Vasc. Anesth.*, 8:515-518.
- Takenoshita, M.; Sugiyama, M.O.; Kuno, Y. et al. (1996) : Anaphylactoid reaction to protamine confirmed by plasma tryptase in diabetic patient during open heart surgery. *Anaesthesiology*, 84:233-235.
- Vander Salm, T.; Kaur, S.; Lancey, R.; Okike, O.; Thom Pezzella, Stahl, R.; Leone, L.; Voler, R. and Michelson, A. (1996) : Effect of CPB on haemostasis. *J. of Thorac Card. Vas. Surg.*, 112:1098-1107.
- Weitz, J.I. (1997) : Low molecular weight heparins. *N. Engl. J. Med.*, 337:688-698.
- Wenger, R.; Lukasiewicz, H.; Mikuta, B. and Edmunds, L. (1989): Loss of platelet fibrinogen receptors during cardio-pulmonary bypass. *J. Thorac. Cardiovas. Surg.*, 69:235-9.
- Wolf, D.; Paul, S.; Micheal, Z. et al. (2001) : Anaphylactic reactions to aprotinin re-exposure in cardiac surgery. *Anaesthesiology*, 95:64-71.



- Wolters, K. (2000) :** Antiplatelet and anticoagulants. In : Drug Facts and Comparison. 4th ed. Wolters Kluwer Company, pp. 55-76.
- Wukk, Thagarajan, P. (1996) :** Role of endothelium in thrombosis and hemostasis. *Ann. Rev. Med.*, 47:315.
- Young, J.A.; Kisher, T.; and Doty, D.B. (1978) :** Adequate anticoagulation during cardipulmonary bypass determined by activated clotting time and the appearance of fibrin monomers. *Ann. Thorac. Surg.*, 26:231.